Logo image of ACRV

ACRIVON THERAPEUTICS INC (ACRV) Stock Fundamental Analysis

NASDAQ:ACRV - US0048901096 - Common Stock

1.33 USD
-0.03 (-2.21%)
Last: 8/28/2025, 5:32:39 PM
1.4 USD
+0.07 (+5.26%)
After Hours: 8/28/2025, 5:32:39 PM
Fundamental Rating

3

Taking everything into account, ACRV scores 3 out of 10 in our fundamental rating. ACRV was compared to 547 industry peers in the Biotechnology industry. No worries on liquidiy or solvency for ACRV as it has an excellent financial health rating, but there are worries on the profitability. ACRV is valued expensive and it does not seem to be growing.


Dividend Valuation Growth Profitability Health

Quickly go to:

1

1. Profitability

1.1 Basic Checks

In the past year ACRV has reported negative net income.
ACRV had a negative operating cash flow in the past year.
In the past 5 years ACRV always reported negative net income.
In the past 5 years ACRV always reported negative operating cash flow.
ACRV Yearly Net Income VS EBIT VS OCF VS FCFACRV Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2020 2021 2022 2023 2024 -20M -40M -60M -80M

1.2 Ratios

ACRV has a Return On Assets (-54.20%) which is comparable to the rest of the industry.
The Return On Equity of ACRV (-60.09%) is better than 60.88% of its industry peers.
Industry RankSector Rank
ROA -54.2%
ROE -60.09%
ROIC N/A
ROA(3y)-33.95%
ROA(5y)-71.69%
ROE(3y)-37.89%
ROE(5y)-107.72%
ROIC(3y)N/A
ROIC(5y)N/A
ACRV Yearly ROA, ROE, ROICACRV Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2020 2021 2022 2023 2024 -100 -200 -300 -400

1.3 Margins

ACRV does not have Profit Margin and Operating Margin and Gross Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM N/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
ACRV Yearly Profit, Operating, Gross MarginsACRV Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2020 2021 2022 2023 2024

More info and screens

7

2. Health

2.1 Basic Checks

ACRV has more shares outstanding than it did 1 year ago.
There is no outstanding debt for ACRV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
ACRV Yearly Shares OutstandingACRV Yearly Shares OutstandingYearly Shares Outstanding 2020 2021 2022 2023 2024 10M 20M 30M
ACRV Yearly Total Debt VS Total AssetsACRV Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2020 2021 2022 2023 2024 50M 100M 150M

2.2 Solvency

ACRV has an Altman-Z score of -1.47. This is a bad value and indicates that ACRV is not financially healthy and even has some risk of bankruptcy.
Looking at the Altman-Z score, with a value of -1.47, ACRV is in line with its industry, outperforming 56.31% of the companies in the same industry.
There is no outstanding debt for ACRV. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -1.47
ROIC/WACCN/A
WACCN/A
ACRV Yearly LT Debt VS Equity VS FCFACRV Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2020 2021 2022 2023 2024 0 50M -50M 100M 150M

2.3 Liquidity

ACRV has a Current Ratio of 10.31. This indicates that ACRV is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of ACRV (10.31) is better than 82.08% of its industry peers.
A Quick Ratio of 10.31 indicates that ACRV has no problem at all paying its short term obligations.
Looking at the Quick ratio, with a value of 10.31, ACRV belongs to the top of the industry, outperforming 82.08% of the companies in the same industry.
Industry RankSector Rank
Current Ratio 10.31
Quick Ratio 10.31
ACRV Yearly Current Assets VS Current LiabilitesACRV Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2020 2021 2022 2023 2024 50M 100M 150M

More info and screens

1

3. Growth

3.1 Past

The Earnings Per Share has grown by an nice 18.77% over the past year.
EPS 1Y (TTM)18.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.77%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A

3.2 Future

ACRV is expected to show a small growth in Earnings Per Share. In the coming years, the EPS will grow by 3.97% yearly.
No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
EPS Next Y7.54%
EPS Next 2Y5.19%
EPS Next 3Y2.31%
EPS Next 5Y3.97%
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A

3.3 Evolution

No Revenue estimates are available, so we could not analyze the future revenue growth and evolution.
ACRV Yearly Revenue VS EstimatesACRV Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2025 2026 2027 2028 2029 2030 2031 2032 100M 200M 300M
ACRV Yearly EPS VS EstimatesACRV Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -2 -4 -6

More info and screens

0

4. Valuation

4.1 Price/Earnings Ratio

The Price/Earnings Ratio is negative for ACRV. In the last year negative earnings were reported.
Also next year ACRV is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
ACRV Price Earnings VS Forward Price EarningsACRV Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 20 40 60

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
ACRV Per share dataACRV EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4

4.3 Compensation for Growth

PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y5.19%
EPS Next 3Y2.31%

More info and screens

0

5. Dividend

5.1 Amount

No dividends for ACRV!.
Industry RankSector Rank
Dividend Yield N/A

More info and screens

ACRIVON THERAPEUTICS INC

NASDAQ:ACRV (8/28/2025, 5:32:39 PM)

After market: 1.4 +0.07 (+5.26%)

1.33

-0.03 (-2.21%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)08-13 2025-08-13/amc
Earnings (Next)N/A N/A
Inst Owners54.82%
Inst Owner Change-21.57%
Ins Owners8.38%
Ins Owner Change-2.05%
Market Cap41.84M
Analysts82.67
Price Target11.39 (756.39%)
Short Float %2.79%
Short Ratio2.12
Dividend
Industry RankSector Rank
Dividend Yield N/A
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)15.09%
Min EPS beat(2)8.02%
Max EPS beat(2)22.15%
EPS beat(4)3
Avg EPS beat(4)10.49%
Min EPS beat(4)-0.13%
Max EPS beat(4)22.15%
EPS beat(8)6
Avg EPS beat(8)8.16%
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-1.47%
PT rev (3m)-2.9%
EPS NQ rev (1m)-0.3%
EPS NQ rev (3m)18.9%
EPS NY rev (1m)2.33%
EPS NY rev (3m)8.02%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)0%
Revenue NY rev (3m)0%
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S N/A
P/FCF N/A
P/OCF N/A
P/B 0.29
P/tB 0.29
EV/EBITDA N/A
EPS(TTM)-2.25
EYN/A
EPS(NY)-2.18
Fwd EYN/A
FCF(TTM)-2.33
FCFYN/A
OCF(TTM)-2.25
OCFYN/A
SpS0
BVpS4.55
TBVpS4.55
PEG (NY)N/A
PEG (5Y)N/A
Profitability
Industry RankSector Rank
ROA -54.2%
ROE -60.09%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM N/A
FCFM N/A
ROA(3y)-33.95%
ROA(5y)-71.69%
ROE(3y)-37.89%
ROE(5y)-107.72%
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexcg growth 3YN/A
ROICexcg growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score5
Asset Turnover0
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr 197.25%
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 10.31
Quick Ratio 10.31
Altman-Z -1.47
F-Score5
WACCN/A
ROIC/WACCN/A
Cap/Depr(3y)372.74%
Cap/Depr(5y)383.65%
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)18.77%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%-5.77%
EPS Next Y7.54%
EPS Next 2Y5.19%
EPS Next 3Y2.31%
EPS Next 5Y3.97%
Revenue 1Y (TTM)N/A
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%N/A
Revenue Next YearN/A
Revenue Next 2YN/A
Revenue Next 3YN/A
Revenue Next 5YN/A
EBIT growth 1Y-23.73%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next YearN/A
EBIT Next 3YN/A
EBIT Next 5YN/A
FCF growth 1Y-96.92%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-94.85%
OCF growth 3YN/A
OCF growth 5YN/A